Purple Book reference family · 351(a) biologic
Botulism Antitoxin Bivalent (Equine) Types A and B.
Botulism Antitoxin Bivalent (Equine) Types A and B. is an FDA-licensed reference biologic from Sanofi Vaccines Canada Ltd..
351(a) biologicBLA 103937 Sanofi Vaccines Canada Ltd.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2000
Reference product
Originator biologic
351(a)BLA 103937
Not listed Botulism Antitoxin Bivalent (Equine) Types A and B.
Sanofi Vaccines Canada Ltd.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference Botulism Antitoxin Bivalent (Equine) Types A and B. product.
26 yr 10 mo ago
Botulism Antitoxin Bivalent (Equine) Types A and B.: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for Botulism Antitoxin Bivalent (Equine) Types A and B..
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
